Today: 20 March 2026
Subscribe
Browse Category

Pharmaceuticals 11 November 2025 - 17 November 2025

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer launched Rimegepant ODT, a migraine tablet, in India, targeting a $200 million market. Shares traded near $25.28, down 55% from late 2022, with a dividend yield around 7%. Analysts maintain a “Hold” rating and see limited short-term movement. The new product addresses migraine in adults unresponsive to standard treatments.
17 November 2025
··
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals said its fibromyalgia drug TONMYA is now available by prescription across the U.S. Shares of Tonix (NASDAQ: TNXP) rose nearly 8% in early trading, reaching $17.16. TONMYA, approved by the FDA in August 2025, is the first new fibromyalgia therapy in over 15 years. The company reported the launch in a Form 8-K filing with the SEC.
17 November 2025
··
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals reported that a triple-drug combination of Aramchol, Stivarga, and metformin sharply increased tumor cell killing in GI cancer models. Shares jumped as much as 38.6% premarket and traded around $1.18 by afternoon, with volume exceeding 41 million shares. The company plans a Phase 1b trial at VCU Massey Comprehensive Cancer Center in early 2026. New U.S. patent applications have been filed for the combination.
17 November 2025
···
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash, expanding its oncology portfolio. Halda’s lead drug candidate targets advanced prostate cancer. The deal is expected to close in the coming months, pending regulatory approval. J&J faces declining Stelara sales as biosimilar competition increases.
17 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Eli Lilly shares traded near $1,025 on Nov. 15, valuing the company just under $1 trillion. The White House announced a deal to lower Zepbound prices and expand public access, while Lilly expects FDA approval of its oral GLP‑1 pill by March 2026. Q3 revenue rose 54% to $17.6 billion. Lilly Endowment filed stock sales around the $1,000 level this month.
15 November 2025
·
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson have halted the Phase 3 Librexia ACS trial of milvexian in acute coronary syndrome after an interim review showed the drug was unlikely to meet its main efficacy goal. BMY shares fell following the announcement. No new safety issues were reported. The trial had aimed to enroll about 16,000 patients worldwide.
14 November 2025
···
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
13 November 2025
····
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer shares rose 1.4% to $25.87 Thursday after the company moved to sell its remaining 4.55 million BioNTech ADRs, potentially raising over $500 million. The stock traded between $25.26 and $25.95, with a market cap near $147 billion and a forward dividend yield of about 6.6–7%. BioNTech shares fell on the news. Investors also weighed Pfizer’s recent $10 billion Metsera deal.
13 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock Today, November 12, 2025: Shares Nudge Higher as Jefferies Webcast Set, Metsera Deal Stays in Focus

Pfizer shares rose 1.7% to $25.94 Wednesday afternoon, trading in a narrow range ahead of next week’s CFO webcast at the Jefferies London Healthcare Conference. Investors are watching for updates on Pfizer’s $10 billion Metsera obesity-drug deal, with a shareholder vote set for November 13. Pfizer recently raised its 2025 EPS outlook and declared a $0.43 Q4 dividend. Market sentiment improved after positive media commentary.
12 November 2025
···
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals priced a $7 million underwritten public offering, with closing contingent on its merger with Decoy Therapeutics. The deal includes common shares, pre-funded warrants, and fixed-price Series A and B warrants. Shares plunged up to 51% Tuesday after the financing news, then rebounded over 50% pre-market and up to 65% intraday today. The merger is expected to close around November 12, 2025.
12 November 2025
···
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck shares rose Wednesday after Phase 3 data showed its oral PCSK9 inhibitor enlicitide cut LDL-C by up to 59.7% and matched placebo for safety. The FDA also cleared Promega’s OncoMate MSI Dx as a companion diagnostic for Keytruda plus Lenvima in advanced endometrial carcinoma. JAMA published peer-reviewed results for enlicitide in HeFH.
12 November 2025
··
Bayer Q3 2025: Adjusted Profit Jumps as Company Books €934m in Litigation Charges—Guidance Intact, Shares Rise

Bayer Q3 2025: Adjusted Profit Jumps as Company Books €934m in Litigation Charges—Guidance Intact, Shares Rise

Bayer reported a 20.8% rise in adjusted third-quarter EBITDA to €1.51 billion, beating analyst forecasts, as revenue reached €9.66 billion. The company booked €934 million in special charges, mostly for U.S. litigation, and raised its full-year special items estimate to up to €4 billion. Bayer kept its profit outlook unchanged. Shares rose as much as 5% intraday.
12 November 2025
···
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Moderna shares rose mid-session Tuesday after UBS cited 2026 upside tied to cost cuts and pipeline progress. Redburn Atlantic lowered its price target to $36, while Bernstein reiterated a $25 target and neutral view, highlighting the need for further expense reductions. The moves follow last week’s Q3 report, which showed a narrower loss and tighter 2025 guidance.
11 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Pfizer will acquire Metsera for up to $10 billion, offering $65.60 per share in cash plus contingent value rights, with a shareholder vote set for Nov. 13. Metsera’s board favored Pfizer over Novo Nordisk after FTC antitrust concerns tipped the balance. Pfizer shares rose about 4–5% to $25.50 following the news. The company also announced seven new trials for its PD‑1×VEGF bispecific antibody, including a phase 3 lung cancer study.
11 November 2025
···
1 … 31 32 33 34 35 … 38

Stock Market Today

  • U.S. Natural Gas Prices Drop on Warmer Weather, Supply Factors Sustain Pressure
    March 20, 2026, 5:19 PM EDT. Natural gas prices for April Nymex delivery fell 2.24% as US weather forecasts turned warmer, potentially lowering heating demand. The Commodity Weather Group predicts above-average temperatures in the western US through March 29, pressuring prices. However, a recent Iranian attack on Qatar's Ras Laffan LNG export facility, which supplies 20% of global liquefied natural gas, could limit further declines. US dry gas production rose 4.8% year-on-year, nearing record highs with rigs increasing to a 2.5-year peak. Inventories surged by 35 billion cubic feet last week, well above average, indicating ample supply. Despite these bearish signals, rising electricity output and export potential from Qatar's damaged plant could support prices amid global supply disruptions.
Go toTop